首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects
【24h】

5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects

机译:新物质vortioxetine(Lu AA21004)的5-HTT和5-HT1A受体占有率。对照对象的PET研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Vortioxetine (Lu AA21004) is a new potential substance for the treatment of anxiety and mood disorders. It has high affinity for the 5-HT transporter (5-HTT) and moderate affinity for the 5-HT1A receptor in vitro. Positron emission tomography (PET) has commonly been used to examine the relation between dose/plasma concentration and occupancy to predict relevant dose intervals in a clinical setting. In this study 11 control subjects were examined with PET and [11C]MADAM at baseline, after a single dose and after 9 days of dosing with Lu AA21004 (2.5, 10 or 60mg) for quantification of 5-HTT occupancy. Four subjects were examined with PET and [11C]WAY 100635 at baseline, after a single dose and after 9 days of dosing of Lu AA21004 (30mg) for quantification of 5-HT1A occupancy. To allow for quantification of binding in the raphe nuclei, PET data were analyzed using wavelet aided parametric imaging. 5-HTT occupancy ranged from 2 (mean, 2.5mg day 1) to 97% (60mg day 9). The apparent affinity of Lu AA21004 binding to 5-HTT (KDND) was calculated to 16.7nM (R=0.95), and the corresponding oral dose (KDND-dose) to 8.5mg (R=0.91). No significant occupancy of 5-HT1A receptors was found after dosing of 30mg Lu AA21004. Based on the literature and the present [11C]MADAM binding data, a dose of 20-30mg Lu AA21004 is suggested to give clinically relevant occupancy of the 5-HTT.
机译:Vortioxetine(Lu AA21004)是治疗焦虑和情绪障碍的一种新的潜在物质。在体外对5-HT转运蛋白(5-HTT)具有高亲和力,对5-HT1A受体具有中等亲和力。正电子发射断层扫描(PET)通常用于检查剂量/血浆浓度与占用率之间的关系,以预测临床环境中的相关剂量间隔。在这项研究中,在基线时,单次给药后和Lu AA21004(2.5、10或60mg)给药9天后,对11名对照受试者的PET和[11C] MADAM进行了基线检查,以定量5-HTT的占用。在单次给药后和给药Lu AA21004(30mg)9天后,对四名受试者进行了PET和[11C] WAY 100635基线检查,以量化5-HT1A的占有率。为了量化在缝核中的结合,使用小波辅助参数成像分析了PET数据。 5-HTT的占用范围从2(平均2.5mg,第1天)到97%(60mg,第9天)。 Lu AA21004与5-HTT(KDND)结合的表观亲和力经计算为16.7nM(R = 0.95),相应的口服剂量(KDND-剂量)为8.5mg(R = 0.91)。给药30mg Lu AA21004后未发现5-HT1A受体的显着占用。根据文献和当前的[11C] MADAM结合数据,建议使用20-30mg Lu AA21004的剂量可产生5-HTT的临床相关占有率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号